We are live on ! Find out more

Genmab

GMAB

Market cap $20.1B

32.65 USD

+0.18

0.55%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

32.65

0.00

1 day

0.55%

5 days

-3.14%

1 month

2.22%

3 months

32.83%

6 months

22.93%

Year to date

2.61%

1 year

16.65%

5 years

-25.47%

10 years

79.59%

About: Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Employees: 3,119

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.3%

Neutral 64.7%

Negative 0%

Neutral

GlobeNewsWire

6 days ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.

Neutral

GlobeNewsWire

6 days ago

Notice to Convene an Extraordinary General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on Wednesday, October 7, 2026, at 3:00 PM CEST at Genmab's offices, Carl Jacobsens Vej 30, 2500 Valby, Denmark. The notice for the Extraordinary General Meeting, including Appendix 1: Shareholder Letter, is attached.

Neutral

GlobeNewsWire

20 days ago

Genmab to Participate in Upcoming Investor Conferences

Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB ) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in September 2026 :

Neutral

GlobeNewsWire

1 month ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.

Neutral

Seeking Alpha

1 month ago

Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript

Positive

MarketBeat

1 month ago

Genmab A/S Q2 Earnings Call Highlights

Genmab A/S NASDAQ: GMAB reported first-half 2026 revenue growth of 25% year over year and raised its full-year financial outlook, citing continued momentum from DARZALEX, EPKINLY and the broader portfolio. The company also outlined upcoming late-stage trial readouts and announced two new Phase III studies of petosemtamab in colorectal cancer.

Positive

Seeking Alpha

1 month ago

Genmab's H1 Preview: Darzalex Beats The Sales Outlook

Genmab's buy rating with a $36 12-month target implies roughly 25% upside from the $28.74 reference price. DARZALEX H1 sales reached $8.17B, already exceeding half of Genmab's $16.0B full-year assumption. Holding Q2 sales flat through H2 would produce $16.59B, above the $16.4B high end of guidance.

Neutral

Business Wire

1 month ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults.

$Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$